

- ***Importance of leading by example in supporting collaboration, not duplicating initiatives already underway. Critical to maintain trust within community and build on existing initiatives in part by involving partners that work in related or similar spaces in early thinking.***
 - ***Focus on what COVID-END can do together that all of us wouldn't be able to do on our own***
 - ***There are important links between the four areas, for example linking the identification of living systematic reviews to horizon scanning. Also potential role for packaging expertise in linking with taxonomy development in navigating towards most accessible product for different decision-makers***
- b. Discuss next priorities to address the terms of reference (see attachment 4)***
- i. Discuss quality appraisal of systematic reviews***
- ***In resources tool, currently only included AMSTAR 2***
 - ***The group reviewed both AMSTAR 1 (limited to RCT design) and AMSTAR 2 (includes both syntheses both RCT and non-RCT studies) and briefly where they might be differently relevant***
 - ***Working group decided to include AMSTAR 1 in the resources tool as another option for quality review***

ACTION ITEM: Share text, link and placement of AMSTAR 1 within resource document to COVID-END webmaster

- ***In thinking about added value of COVID-END, Vivian highlighted importance of equity, particularly in rapid evidence syntheses, and ensuring that that equity, diversity and inclusion analysis is not lost in name of timeliness. Possible to put forward principles, include equity analysis as a measure of quality.***
- ***The group agreed to discuss this more detail at next week's meeting.***